Canlyniadau Chwilio - M. Dror Michaelson

Mireinio'r Canlyniadau
  1. 1
    Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer

    Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer gan Philip J. Saylor, Donald S. Kaufman, M. Dror Michaelson, Richard J. Lee, Matthew R. Smith

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Management of Complications of Prostate Cancer Treatment

    Management of Complications of Prostate Cancer Treatment gan M. Dror Michaelson, S. E. Cotter, Patricio C. Gargollo, Anthony L. Zietman, Douglas M. Dahl, Mitchell R. Smith

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma

    Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma gan C. de Bazelaire, David C. Alsop, Daniel J. George, Iván Pedrosa, Yongyu Wang, M. Dror Michaelson, Neil M. Rofsky

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

    Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis... gan David Cella, M. Dror Michaelson, Andrew G. Bushmakin, Joseph C. Cappelleri, Claudie Charbonneau, S T Kim, J Z Li, Robert J. Motzer

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

    A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC) gan Ana M. Molina, Thomas E. Hutson, James Larkin, Anne Gold, Karen Wood, Dave Carter, Robert J. Motzer, M. Dror Michaelson

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

    Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinom... gan Sujata Patil, Robert A. Figlin, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, S.T. Kim, Xin Huang, Robert J. Motzer

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

    Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer gan M. Dror Michaelson, Donald S. Kaufman, Hang Lee, Francis J. McGovern, Philip W. Kantoff, Mary Anne Fallon, Joel S. Finkelstein, Matthew R. Smith

    Cyhoeddwyd 2007
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Human Kidney Injury Molecule-1 Is a Tissue and Urinary Tumor Marker of Renal Cell Carcinoma

    Human Kidney Injury Molecule-1 Is a Tissue and Urinary Tumor Marker of Renal Cell Carcinoma gan Won Kon Han, Anwar Alinani, Chin‐Lee Wu, M. Dror Michaelson, Massimo Loda, Francis J. McGovern, Ravi Thadhani, Joseph V. Bonventre

    Cyhoeddwyd 2005
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Phase II study of sunitinib in men with advanced prostate cancer

    Phase II study of sunitinib in men with advanced prostate cancer gan M. Dror Michaelson, Meredith M. Regan, William Oh, Donald S. Kaufman, Kara Olivier, Simon Michaelson, Beverly Spicer, Carol Gurski, Philip W. Kantoff, Matthew Smith

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients

    Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients gan Jonathan E. Rosenberg, Vivian Weinberg, William K. Kelly, M. Dror Michaelson, Maha Hussain, George Wilding, Mitchell E. Gross, Douglass Hutcheon, Eric J. Small

    Cyhoeddwyd 2007
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

    Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins gan Samuel E. DePrimo, Carlo L. Bello, John Smeraglia, Charles M. Baum, Dominic G. Spinella, Brian I. Rini, M. Dror Michaelson, Robert J. Motzer

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

    Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients gan Frede Donskov, M. Dror Michaelson, Igor Puzanov, Mellar P. Davis, Georg A. Bjarnason, Robert J. Motzer, David Goldstein, Xun Lin, Darrel P. Cohen, Robin Wiltshire, Brian I. Rini

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma

    Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma gan M. Dror Michaelson, Rana R. McKay, Lillian Werner, Michael B. Atkins, Eliezer M. Van Allen, Kara Olivier, Jiaxi Song, Sabina Signoretti, David F. McDermott, Toni K. Choueiri

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases

    A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases gan Richard J. Lee, Philip J. Saylor, M. Dror Michaelson, S. Michael Rothenberg, Malgorzata E. Smas, David T. Miyamoto, Carol Gurski, Wanling Xie, Shyamala Maheswaran, Daniel A. Haber, Jonathan Goldin, Matthew R. Smith

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

    NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy gan Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim Margolin, M. Dror Michaelson, Robert J. Motzer, Роберто Пили, Susan K. Roethke, Sandy Srinivas

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

    A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma gan Thomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit Jain, Mayer Fishman

    Cyhoeddwyd 2021
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

    Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma gan Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, Gary R. Hudes, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Sindy T. Kim, Xin Huang, James A. Williams, Tim Eisen, Robert J. Motzer

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Sunitinib rechallenge in metastatic renal cell carcinoma patients

    Sunitinib rechallenge in metastatic renal cell carcinoma patients gan Ivan Zama, Thomas E. Hutson, Paul Elson, James M. Cleary, Toni K. Choueiri, Daniel Y.C. Heng, Nikhil H. Ramaiya, M. Dror Michaelson, Jorge A. García, Jennifer J. Knox, Bernard Escudier, Brian I. Rini

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

    Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma gan Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial gan Toni K. Choueiri, Susan Halabi, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Meghara Walsh, Darren R. Feldman, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Dakhil, Daniel J. George, Michael J. Morris

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: